Wells Fargo & Company MN Sells 114,324 Shares of Takeda Pharmaceutical Company Limited (NYSE:TAK)

Wells Fargo & Company MN decreased its holdings in shares of Takeda Pharmaceutical Company Limited (NYSE:TAK - Free Report) by 11.7% during the 4th quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The fund owned 863,678 shares of the company's stock after selling 114,324 shares during the quarter. Wells Fargo & Company MN's holdings in Takeda Pharmaceutical were worth $11,435,000 as of its most recent SEC filing.

Several other institutional investors and hedge funds have also modified their holdings of the business. Versant Capital Management Inc acquired a new position in Takeda Pharmaceutical during the 4th quarter worth $26,000. Wilmington Savings Fund Society FSB bought a new stake in shares of Takeda Pharmaceutical in the 3rd quarter valued at approximately $40,000. BNP Paribas Financial Markets grew its position in Takeda Pharmaceutical by 416.0% in the third quarter. BNP Paribas Financial Markets now owns 3,220 shares of the company's stock valued at $46,000 after acquiring an additional 2,596 shares during the period. Farther Finance Advisors LLC grew its holdings in shares of Takeda Pharmaceutical by 123.6% in the 4th quarter. Farther Finance Advisors LLC now owns 3,575 shares of the company's stock worth $47,000 after purchasing an additional 1,976 shares during the last quarter. Finally, Crowley Wealth Management Inc. acquired a new stake in shares of Takeda Pharmaceutical during the fourth quarter worth approximately $52,000. Institutional investors and hedge funds own 9.17% of the company's stock.

Takeda Pharmaceutical Trading Up 0.2 %

NYSE TAK traded up $0.04 on Friday, reaching $14.69. The company had a trading volume of 1,971,072 shares, compared to its average volume of 1,855,073. Takeda Pharmaceutical Company Limited has a 52 week low of $12.58 and a 52 week high of $15.37. The stock's 50 day moving average is $14.57 and its 200-day moving average is $13.91. The company has a quick ratio of 0.72, a current ratio of 1.31 and a debt-to-equity ratio of 0.63. The stock has a market cap of $46.73 billion, a price-to-earnings ratio of 36.71, a PEG ratio of 0.24 and a beta of 0.39.

Takeda Pharmaceutical (NYSE:TAK - Get Free Report) last posted its earnings results on Thursday, January 30th. The company reported $0.42 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $0.34 by $0.08. Takeda Pharmaceutical had a return on equity of 9.39% and a net margin of 4.53%. Equities analysts predict that Takeda Pharmaceutical Company Limited will post 1.64 earnings per share for the current year.

Wall Street Analyst Weigh In

Separately, Morgan Stanley upgraded shares of Takeda Pharmaceutical from an "equal weight" rating to an "overweight" rating in a research report on Wednesday, April 2nd.

About Takeda Pharmaceutical

Takeda Pharmaceutical Company Limited engages in the research, development, manufacture, marketing, and out-licensing of pharmaceutical products in Japan and internationally. It offers pharmaceutical products in the areas of gastroenterology, rare diseases, plasma derived therapies, immunology, oncology, and neuroscience.